Cavalry Biosciences seeks $75M Series B to advance eye and muscle disorder candidates
read at Endpoints ↗DealPositive
Cavalry Biosciences, the first company emerging from the Jupiter Bioventures incubator, announced it is pursuing a $75 million Series B financing round.
The capital is intended to move its first two drug candidates, which target eye and muscle disorders, into clinical testing phases.
CEO Preston Klassen told Endpoints that the funding will support the early development of these programs, marking a key milestone for the young biotech.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs”
read at Endpoints ↗89 words · retrieved Jun 8
comments(0)
5-min edit window · permanent after that